Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2014

View Archived Issues

UCP2 -866G/A polymorphism and genotypes as prognostic markers for ischemic stroke

Novel dual histamine H1/H4 antagonists presented for allergic conjunctivitis

New company Nurix launched with focus on the ubiquitin proteasome system

BioRestorative Therapies signs research agreement with Pfizer

IXICO gains additional Huntington's disease trial contracts

Novel TNF-alpha-expressing oncolytic adenovirus demonstrates antitumor activity

Pharmaxis' LOXL2 inhibitors show promise for fibrosis

U.S. researchers prepare novel nucleosides and prodrugs

CHMP adopts positive opinion for Plegridy as a treatment for multiple sclerosis

Retriacyl obtains FDA orphan drug status for RP

Salk's Glenn Center for Aging Research receives USD 3 million gift

Viking Therapeutics licenses five programs from Ligand Pharmaceuticals

Daiichi Sankyo receives additional indication approval in Japan for Ranmark

European researchers disclose new anti-S100-A4 MAbs

Shionogi patents novel AMPK activators for diabetes

Boehringer Ingelheim patent reports new CMV inhibitors

New E-selectin inhibitors designed by GlycoMimetics

FDA approves EkoSonic endovascular system

EMA committee makes Halaven recommendation

EMA's CHMP recommends approval of Simbrinza to reduce IOP

EMA committee hands down positive opinion on Arzerra for CLL

EMA recommends approval of Nuwiq for children and adults with hemophilia A

Elixir Medical presents results on CE Mark-approved novolimus-eluting coronary intervention systems

Pfizer rules out new offer for AstraZeneca

Taliglucerase alfa approved in Australia for Gaucher's disease

EMA's CHMP confirms negative opinion for RLX-030

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...